SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online.
More information about this event, including access to the live webcast link (available soon) and an RSVP link to request to attend the event in person, may be accessed by visiting https://investor.resmed.com. The webcast replay will be available shortly after the live webcast ends and will be accessible for the following thirty (30) days.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors +1 858.836.5000 This email address is being protected from spambots. You need JavaScript enabled to view it. | For media +1 619.510.1281 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$247.19 |
| Daily Change: | 0.31 0.13 |
| Daily Volume: | 1,047,597 |
| Market Cap: | US$36.070B |
October 30, 2025 August 27, 2025 August 18, 2025 May 01, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
